Chemogenomics - www.biofocus.com

Our chemogenomics division, Chematica, is a powerful proprietary informatics approach to drug discovery, which combines the chemical and biological information from our vast drug discovery-relevant databases. Access to Chematica provides your organization with comprehensive data and knowledge, accessed using the best analysis tools, to enhance your R&D efficiencies. Chematica's prime function is to enable selection of the best biological targets based on intrinsic target drugability and identification of the most appropriate drug-like chemistry starting points to address them.

Chematica consists of three major products - DrugStore, StARLITe, SARfari - which are optimized for data-mining and integration of third-party data and consist of expertly curated information:

• DrugStore: database of activities and properties of known drugs

• StARLITe: database of bio-active compounds, biological targets and pharmalogical effects

• SARfari: integrated discovery tools, including GPCR SARfari (a database of all GPCR targets and known ligands and activities) and Kinase SARfari (a database of protein kinase targets and compounds that modify kinase activity)

Efficient
Selecting only drugable targets to work with, at the onset of a discovery program, focuses resources on projects with the highest chance of success and saves considerable effort being wasted on projects with a high risk of failure.

The Chematica system combines the expertise and know-how of our staff with proprietary tools and knowledge bases to assist our clients to develop their target and lead selection projects in the most efficient way.

Comprehensive
Chematica is robust and scalable, permitting analysis of one or many potential targets, with simultaneous exploration of compound potency and selectivity. The system can be used to find potential off-target compound effects both within and outside the selected target protein family.

Effective
Chematica has been commercially validated by successful collaborations with Pfizer, Novartis, P & G Pharmaceuticals, Daiichi Pharmaceuticals, Serono and others.

Easily accessible
Chematica can be accessed through tailored research collaborations, projects, services or via licensing components of the technology.

For further details on our chemogenomic predictive drug discovery technologies, download the Chematica brochure or contact us.

Chematica™, StARLITe™, DrugStore™ and SARfari™ are trademarks of Galapagos NV and/or its affiliates.


search Target discovery Hit finding biology Hit finding chemistry Hit-to-lead/Lead optimization Predictive drug discovery Chemogenomics - DrugStore - StARLITe - SARfari StarDrop Compound management Partnerships About us News and events Careers Contact BioFocus DPI Home Galapagos Home Mailing list	Our chemogenomics division, Chematica, is a powerful proprietary informatics approach to drug discovery, which combines the chemical and biological information from our vast drug discovery-relevant databases. Access to Chematica provides your organization with comprehensive data and knowledge, accessed using the best analysis tools, to enhance your R&D efficiencies. Chematica's prime function is to enable selection of the best biological targets based on intrinsic target drugability and identification of the most appropriate drug-like chemistry starting points to address them. Chematica consists of three major products - DrugStore, StARLITe, SARfari - which are optimized for data-mining and integration of third-party data and consist of expertly curated information: • DrugStore: database of activities and properties of known drugs • StARLITe: database of bio-active compounds, biological targets and pharmalogical effects • SARfari: integrated discovery tools, including GPCR SARfari (a database of all GPCR targets and known ligands and activities) and Kinase SARfari (a database of protein kinase targets and compounds that modify kinase activity) Efficient Selecting only drugable targets to work with, at the onset of a discovery program, focuses resources on projects with the highest chance of success and saves considerable effort being wasted on projects with a high risk of failure. The Chematica system combines the expertise and know-how of our staff with proprietary tools and knowledge bases to assist our clients to develop their target and lead selection projects in the most efficient way. Comprehensive Chematica is robust and scalable, permitting analysis of one or many potential targets, with simultaneous exploration of compound potency and selectivity. The system can be used to find potential off-target compound effects both within and outside the selected target protein family. Effective Chematica has been commercially validated by successful collaborations with Pfizer, Novartis, P & G Pharmaceuticals, Daiichi Pharmaceuticals, Serono and others. Easily accessible Chematica can be accessed through tailored research collaborations, projects, services or via licensing components of the technology. For further details on our chemogenomic predictive drug discovery technologies, download the Chematica brochure or contact us. Chematica™, StARLITe™, DrugStore™ and SARfari™ are trademarks of Galapagos NV and/or its affiliates.	Related links Chematica brochure BioFocus DPI Home Galapagos Home